Scorpion Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Scorpion Therapeutics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Scorpion Therapeutics presents a practical BD-screening case because its returned pipeline contains 4 records and the deal search returned 3 transaction records. The lead returned asset is Elticertinib, associated with EGFR exon 20 x HER2 and EGFR ex20ins mutation in non-small cell lung cancer, Non-Small Cell Lung Cancer, at Phase 2. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Elticertinib | Scorpion Therapeutics, Inc. | Phase 2 | Pipeline record: EGFR exon 20 x HER2; EGFR ex20ins mutation in non-small cell lung cancer, Non-Small Cell Lung Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program | Phase 2 asset with EGFR exon 20 x HER2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | STX-241 | Scorpion Therapeutics, Inc. | Preclinical | Pipeline record: EGFR exon 21 mutation x EGFR-Ex19del; Non-Small Cell Lung Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets | Preclinical asset with EGFR exon 21 mutation x EGFR-Ex19del exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | WO2024086804 | Scorpion Therapeutics, Inc. | Discovery | Pipeline record: p53; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets | Discovery asset with p53 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | WO2024086809 | Scorpion Therapeutics, Inc. | Discovery | Pipeline record: p53 Y220C; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program | Discovery asset with p53 Y220C exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2025-01-13 | Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program | Completed | total_amount: 2500; disclosed: false |
| 2023-04-04 | Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets | Active | upfront_payment: 65; total_amount: 553; disclosed: true |
| 2022-01-13 | AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets | Active | upfront_payment: 75; disclosed: true |
The most relevant returned precedent is: Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program (2025-01-13). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Precision Therapeutics Inc. - Prospectus(U.S. Stocks): Precision Therapeutics Inc. - Prospectus(U.S. Stocks) The Company Sold through the Skyline Medical business of Precision Therapeutics, The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical’s STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departmen
- TITAN PHARMACEUTICALS INC - Prospectus(U.S. Stocks): TITAN PHARMACEUTICALS INC - Prospectus(U.S. Stocks) Table of Contents We may need additional financing. At September 30, 2006, we had approximately $17 million of cash, cash equivalents, and marketable securities. Our financing agreement with Cornell Capital Partners can provide us with up to an additional $31.0 million, subject to shareholder approval for certain amounts under this agreement. It is likely that we will need to seek additional financing to continue our product development activities, and will be required to obtain substantial funding to commercialize any products other than iloperidone or Spheramine that we may successfully develop. Other than the Standby Equity Distribution Agreement with Cornell Capital Partners, we do not have any funding commitments or arrangements. If
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Scorpion Therapeutics is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Scorpion Therapeutics merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Elticertinib, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
